Management of metastatic castration-resistant prostate cancer

Research output: Contribution to journalArticlepeer-review


The management of men with metastatic castration-resistant prostate cancer (CRPC) has taken several leaps forwards in the last two years, with the demonstration of improved overall survival with three novel agents (sipuleucel-T, cabazitaxel and abiraterone acetate) and a significant delay in skeletal-related events observed with denosumab. The pipeline of systemic therapies in prostate cancer remains strong, as multiple agents with a diverse array of mechanisms of action are demonstrating preliminary signs of clinical benefit, leading to more definitive Phase III confirmatory trials. In this review, we will discuss the evolving landscape of treatment options for men with CRPC, with a particular focus on currently approved and emerging treatment options for these patients. Knowledge of these evolving standards will help to optimise delivery of care and long-term outcomes in men with advanced CRPC.

Original languageEnglish (US)
Pages (from-to)90-97
Number of pages8
JournalEuropean Urological Review
Issue number2
StatePublished - Dec 1 2011


  • Abiraterone
  • Cabazitaxel
  • Castration-resistant prostate cancer
  • Denosumab
  • Drug development
  • Ipilimumab
  • MDV3100
  • Novel therapies
  • Orteronel
  • Sipuleucel-T

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Management of metastatic castration-resistant prostate cancer'. Together they form a unique fingerprint.

Cite this